Skip to content

A plant based Ayurvedic medicine used for the prevention and management of various risk factors responsible for occurrence of Coronary Heart Disease.

A randomized double blind controlled clinical trial of an Ayurvedic formulation for the prevention and management of coronary heart disease.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/01/005397
Enrollment
1000
Registered
2015-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Coronary Heart Disease

Interventions

Intervention1: The shed dried root of Withania somnifera, rhizome of Costus speciosus, bark of Terminalia arjuna and fruits of Hippophae rhamnoides was utilized for hydro-methanolic extract and active

Sponsors

Department of Science Technology
Lead Sponsor
Prof N Sethuraman
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of CHD consenting to participate in clinical drug trial program were included in the study. These CHD patient showing dyslipidemia, atherosclerotic, ischemic changes, elevated homocysteine and inflammatory markers, concentration with certain psychological complaints mainly sleep disturbances were treated with test formulation. The diagnosis of CHD patients were done on the basis of clinical as well as laboratory findings.

Exclusion criteria

Exclusion criteria: Patients suffering from chronic illness like T.B., Rheumatoid arthritis, diagnosed IHD cases; Type-1 diabetic patients; Evidence of hypo or hyperthyroidism; Age above 75 years.

Design outcomes

Primary

MeasureTime frame
The test formulation has shown Cardio-protective property through its anti-atherosclerotic, anti-inflammatory, anti-obesity activityTimepoint: Parameters measured at baseline (initial), 3 months and 6 months

Secondary

MeasureTime frame
The test formulation has shown reduction in anxiety level as well as improved sleep pattern among CHD patientsTimepoint: Parameters measured at baseline (initial), 3 months and 6 months

Countries

India

Contacts

Public ContactDr R C Satish Kumar

Interdisciplinary School of Indian System of Medicine

ilangok67@gmail.com9042728777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026